{
    "clinical_study": {
        "@rank": "129479", 
        "arm_group": [
            {
                "arm_group_label": "Bevacizumab,postoperative chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk\u3001Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.\nGroups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk\u3001Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.\nplacebo:Physiological saline"
            }, 
            {
                "arm_group_label": "Preoperative Chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk\u3001Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.\nGroups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk\u3001Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.placebo:Physiological saline"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators assessed whether the addition of a preoperative regimen of Bevacizumab\n      regimen to improves R0 resection rate and survival among patients with potentially\n      resectable gastric cancer with liver metastasis."
        }, 
        "brief_title": "Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Gastric Cancer", 
            "Liver Metastasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Stomach Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Liver Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Groups 1:Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially\n      Resectable Gastric Cancer With Liver Metastasis.\n\n      Groups 2:Capecitabine Plus Oxaliplatin  With placebo in Patients With Potentially Resectable\n      Gastric Cancer With Liver Metastasis.\n\n      Group 1 compare with Group 2 in disease-free survival time. Stage I\uff1aPreoperative therapy\n      Capecitabine Plus Oxaliplatin With Bevacizumab is superior to Capecitabine Plus Oxaliplatin\n      alines.\n\n      Stage II: therapy after surgery Capecitabine Plus Oxaliplatin With Bevacizumab is superior\n      to Capecitabine Plus Oxaliplatin alones after surgery for over 6 months in all."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1.Pathological tissue were gastric cancer by gastric and liver biopsy.\n\n             2.Immunohistochemistry confirmed HER-2 ( - ).\n\n             3.The number of liver metastasis is less than 3 and evey one is less than 5 cm.\n\n             4.Liver metastasis must be clinically limited to Type H1 or Type H2.\n\n             5.gastric cancer were able to resectable lesions or T1-4a N1-2 M0.\n\n             6.Patients\u2022had not received radiotherapy past and not other organ metastasis and\n             peritoneal metastasis.\n\n             7.Karnofsky performance status performance status >70.\n\n             8.Inadequate hematopoietic function\uff1a Hemoglobin\u226590g/L;\n             ANC\u22651,500/mm3;Platelet\u2265100,000/mm3\n\n             9.Inadequate organ function which is defined as below: Total bilirubin\u22641.5 pper limit\n             of normal range (ULN);alanine transaminase / Aspertate aminotransferase\u22642.5 upper\n             limit of normal range (ULN) (\u22645.0 x ULN if hepatic metastasis); serum creatinine\u22641.5\n             pper limit of normal range (ULN), Serum albumin\u226530g/L.\n\n             10.expectancy must be more than 3 months.\n\n             11.the random blood or urine pregnancy test in fertile woman must be the negative\n             results in pregnancy test in 7 days.\n\n             12.Patients for male and female used reliable contraception contraceptive method\n             until the end of study 30 days later.\n\n        Type H1: only one leaf with liver metastasis. Type H2: two leaves with a few scattered\n        metastatic in liver.\n\n        Exclusion Criteria:\n\n          -  1. Patients with other extrahepatic metastasis Include peritoneal metastasis.\n\n             2. Primary was ulcerative type or the existence of the perforation.\n\n             3. Patients with other malignancy in 5 years.\n\n             4. Patients with severe liver disease, kidney disease, respiratory disease ,\n             uncontrolled diabetes or severe infections.\n\n             5.Patients with hypertension failed to control, active bleeding, 3~4 proteinuria,\n             heal the wound, thromboembolisms, heart failure, clinical symptoms of heart disease.\n\n             6.Patients have obvious peripheral nervous system disorders,mental disorders and\n             disorders of the central nervous system history.\n\n             7.Patients have history of organ transplantation.\n\n             8.Patients with any medical or psychiatric condition or disease which, in the\n             investigator's judgment, would make the patient inappropriate for entry into this\n             study.\n\n             9.Patients combined antitumor drug outside the research program."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01962376", 
            "org_study_id": "YZHANG0001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Bevacizumab,postoperative chemotherapy", 
                    "Preoperative Chemotherapy"
                ], 
                "description": "A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk\u3001Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.", 
                "intervention_name": "Oxaliplatin;Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Oxaliplatin plus capecitabine other names:XELOX."
            }, 
            {
                "arm_group_label": [
                    "Bevacizumab,postoperative chemotherapy", 
                    "Preoperative Chemotherapy"
                ], 
                "description": "A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk\u3001Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.", 
                "intervention_name": "Oxaliplatin;Capecitabine;Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Capecitabine Plus Oxaliplatin Other names XELOX."
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Capecitabine", 
                "Bevacizumab", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Capecitabine", 
            "Oxaliplatin", 
            "Bevacizumab", 
            "Potentially Resectable Gastric Cancer Liver Metastasis"
        ], 
        "lastchanged_date": "October 10, 2013", 
        "location": {
            "contact": {
                "email": "13315978336@163.com", 
                "last_name": "Yan Zhang, Doctor", 
                "phone": "+8613315978336"
            }, 
            "facility": {
                "address": {
                    "city": "Shijiazhuang", 
                    "country": "China", 
                    "state": "Hebei", 
                    "zip": "050011"
                }, 
                "name": "Department of Internal Medicine-Oncology"
            }, 
            "investigator": {
                "last_name": "Yan Zhang, Doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis", 
        "other_outcome": [
            {
                "measure": "R0-resection rate", 
                "safety_issue": "No", 
                "time_frame": "within 3 weeks after surgery"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Side effects during observation] Investigators graded all adverse events and toxic effects according to the National Cancer Institute's Common Toxicity Criteria, version 2.0. The number of Participants with adverse events will be recorded at each treatment visit.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "overall_official": {
            "affiliation": "Hebei Medical University", 
            "last_name": "Yan Zhang, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "progression-free survival(PFS)", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01962376"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hebei Medical University", 
            "investigator_full_name": "Yan Zhang", 
            "investigator_title": "The first hospital of Shijiazhuang city", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Objective response rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "within 3 weeks after surgery"
        }, 
        "source": "Hebei Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hebei Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}